Ingen internetforbindelse — viser den gemte version af siden.

Molecular Partner…

CHCHF
← Til Screeneren

Molecular Partners AG (SW:MOLN) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
molecularpartners.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hovedkontor
Schlieren-Zurich, Switzerland
Administrerende Direktør
Patrick Amstutz
Ansatte
134
Børsnoteret Siden
03.03.2015 (SW:MOLN)
Udestående Aktier
38.31 mio.
Free Float
20.71 mio.
Markedsværdi
127.56 mio. CHF
Insidere
8.47%
Institutionelle Investorer
43.8%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Juridisk Form
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
P/E
underskud
FCF
−52.0 mio. CHF
Gæld
?
Indtjening og FCF — for de 12 måneder frem til 31.12.2025 (virksomhedens seneste rapport).
Beskrivelse

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

annonce

Børser og Tickere

BørsTickerValutaPrisType
SW SIX Swiss ExchangeMOLN primærCHF3.33 -0.30%almindelige aktier
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%almindelige aktier
US USA StocksMLLCF OTCUSD4.01 +0.00%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdagHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Største Ejere

EjerAndelAktierRapportdato
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31